$SYK

STRYKER RONDA E sold $96.8M of SYK (indirect holdings)

STRYKER RONDA E sold 310,000 indirectly-held shares of STRYKER CORP (SYK) at an average of $312.23 ($310.77–$315.11, $96.79M total) across 6 trades on 2026-05-26.

Original reporting
SEC EDGAR · STRYKER RONDA E
Published May 28, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:43 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SYK
Neutral
medium confidence
Mentioned
$SYK
Relevance
8/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYKNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or unusual volume, but the disclosure does not change Stryker’s earnings outlook or business fundamentals.

02

Market read

A director’s large open-market sale totaling about $96.8M is newly disclosed, which can influence short-term sentiment but lacks fundamental new information.

03

What to watch

The filing does not state the reason for the sale, and the transaction occurred May 26, so any immediate price impact would depend on whether the market had already anticipated the selling.

Relevance 8/10Novelty 4/10Timing: SEC Form 4 filed May 28, covering sales executed May 26.

Background

The article is an SEC Form 4 insider transaction disclosure for Stryker Corp, reported by a director through indirect holdings.

Company-level read

Ticker impact

$SYKNeutralMedium confidence
Context

Stryker director Ronda E Stryker sold 310,000 shares in an open-market transaction totaling about $96.8M, filed as Form 4.

Expected impact

Likely limited fundamental impact; any price reaction would be sentiment-driven and should fade unless follow-on selling or new company news emerges.

Evidence & confidence

The filing is a primary-source Form 4 disclosure with transaction size and pricing range, but it does not provide new operating or guidance information. The absence of a 10b5-1 plan can increase interpretive risk, yet indirect holdings and routine director liquidity motives often reduce signal strength.

Market effects

Insider selling at a large medtech name can modestly affect sentiment across healthcare/medtech, but no sector-wide catalyst is disclosed.

No specific regional market linkage beyond US-listed medtech sentiment.

No direct global operational or regulatory linkage is provided.

Counterpoint

The sale is indirect and may reflect diversification, tax planning, or estate-related liquidity rather than a bearish view on fundamentals.

Key entities

  • STRYKER CORP

    US-listed medtech company subject of the Form 4 insider sale disclosure.

  • STRYKER RONDA E

    Director reporting an open-market sale of shares held indirectly.

Related articles

$SYKMedAI 8/10

Stryker (SYK) Q2 2026 Earnings Call Transcript

Stryker (SYK) reported Q2 2026 adjusted EPS of $3.69, up 17.9% year over year, with organic net sales up 9% and adjusted gross margin at 66%. Management cited recovery from a prior cybersecurity incident and higher production. Full-year organic net sales guidance is 8.3% to 9.3%, and adjusted EPS guidance is $14.95 to $15.10.

$SYKMedAI 8/10

Why Stryker (SYK) Shares Are Plunging Today

Stryker (SYK) shares fell about 7.3% in the morning after the company reported Q2 results. Revenue rose 9.4% year over year to $6.59 billion, but organic growth of about 9% met only Wall Street expectations and missed forecasts. Adjusted earnings were $3.69 per share, beating estimates by 5.8%, and guidance was slightly raised.

$SYKMedAI 8/10

Stryker nets $6.6bn revenue in Q2; highlights resilience following cyberattack

Stryker has reported Q2 revenues of $6.6bn, denoting a 9.4% rise year-over-year (YoY), with the company's CEO lauding its "significant progress" in recovering since its global operations were disrupted by an cyberattack in March. Following the results, Stryker is tweaking its 2026 outlook at the low end, with earnings now projected to land in the $14.95 to $15.10 per share range, up from $14.90 to $15.10 previously.

$SYKMedAI 8/10

Stryker (SYK) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chair and Chief Executive Officer - Kevin A. Lobo Chief Financial Officer - Preston Wells Vice President of Investor Relations - Nick Mead TAKEAWAYS Organic Net Sales -- 9% growth, reflecting recovery from a previous cybersecurity incident and increased production to meet demand. Adjusted EPS -- $3.69, a 17.9% increase from the same quarter last year, reflecting improved gross margins and operational execution.

$SYKHighAI 9/10

Stryker Q2 adj. EPS hits $5.75, beating $3.49 estimate

Stryker (NYSE: SYK) reported second-quarter 2026 adjusted earnings per share of $5.75, surpassing analyst consensus estimates of $3.49 by 64.76 percent. This result marks an 83.71 percent year-over-year increase from $3.13 in the prior-year period. Consolidated net sales rose 9.42 percent to $6.589 billion, narrowly exceeding the $6.579 billion estimate. The strong performance reflects robust operational execution and expanded margins despite modest revenue growth.

$SYKMed

SYK: Strong Q2 sales and EPS growth, with robust outlook and narrowed full-year guidance

Less than 1 min read Delivered 9% organic sales growth and 17.9% adjusted EPS growth year-over-year, overcoming supply disruptions and a prior cybersecurity incident. Narrowed full-year guidance reflects strong demand, robust backlog, and confidence in production ramp and capital order fulfillment. Based on Stryker Corporation [SYK] Q2 2026 Audio Transcript — Jul. 30 2026 Disclaimer This is an AI-generated summary and may contain inaccuracies.